Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up

Ohnstad, Hege O.; Borgen, Elin; Falk, Ragnhild Sørum; Lien, Tonje G.; Aaserud, Marit; Sveli, My Anh Tu; Kyte, Jon Amund; Kristensen, Vessela N.; Geitvik, Gry Aarum; Schlichting, Ellen; Wist, Erik; Sørlie, Thérese; Russnes, Hege G.; Naume, Bjørn

doi:10.1186/s13058-017-0911-9

Cited by 96 publications

(100 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RT-qPCR assays allow prognosis on the basis of a small number of 'classifier' gene signatures comprising proliferation genes, hormone receptors, and basal markers. Other assays are employed to identify tumor subtypes or to predict recurrence [121][122][123].…”

Section: Gene Expression Assaysmentioning

confidence: 99%

Pregnancy and Breast Cancer: Pathways to Understand Risk and Prevention

Slepicka

Cyrill

Santos

2019

Trends in Molecular Medicine

View full text Add to dashboard Cite

Several studies have made strong efforts to understand how age and parity modulate the risk of breast cancer. A holistic understanding of the dynamic regulation of the morphological, cellular, and molecular milieu of the mammary gland offers insights into the drivers of breast cancer development as well as into potential prophylactic interventions, the latter being a longstanding ambition of the research and clinical community aspiring to eradicate the disease. In this review we discuss mechanisms that react to pregnancy signals, and we delineate the nuances of pregnancyassociated dynamism that contribute towards either breast cancer development or prevention. Further definition of the molecular basis of parity and breast cancer risk may allow the elaboration of tools to predict and survey those who are at risk of breast cancer development. Parity: A Perspective for Therapeutic and Prophylactic InterventionBreast cancer is the most frequently diagnosed malignance in women. It strikes >1.6 million women worldwide, and about one in eight 8 women in the USA will develop breast cancer in their lifetime (Box 1 and Table 1). Most breast cancers arise because of dysfunction of cells in mammary ducts (50-70% of tumors) or lobules (10-15% of breast cancers), which categorizes these tumors as carcinomas, specifically adenocarcinomas. Some breast tumors are sarcomas, originating in the stroma or muscle. Other types and subtypes of breast cancer are less frequent, and a single diagnosis of breast cancer may refer to a combination of different tumors (www.breastcancer.org) (Box 1).Parity is known to have a dual effect on breast cancer risk. In many ways, breast tumorigenesis mimics several mechanisms that are commonly activated during pregnancy, including augmented cell proliferation, alterations in cell shedding, reduced cell apoptosis, altered gene expression, and extracellular matrix (ECM) modifications. On the other hand, epidemiological studies have provided evidence of the cancer-preventive benefits of pregnancy wherein an early age of pregnancy decreases the risk of breast cancer development. Although understanding the molecular mechanisms underlying these phenomena is still in its infancy, their elucidation will open new avenues to target breast cancer. Mammary Gland Composition and DevelopmentThe mammary gland is a complex and highly adaptive organ whose main function, in female mammals, is to produce milk during lactation for the sustenance of young offspring. The gland is composed of a variety of cell types, including fibroblasts, adipocytes, epithelial, endothelial, and immune cells. The epithelial cells can be further subdivided into multiple cell types that, together, form the branching structure of the gland and constitute the secretory alveoli during lactation. Two main epithelial cell compartments can be distinguished in the mammary gland: the luminal compartment [the inner cell layer, localized between the lumen (see Glossary),and the basal compartment] and the basal compartment (the outer layer surrounding ...

show abstract

Section: Gene Expression Assaysmentioning

confidence: 99%

Pregnancy and Breast Cancer: Pathways to Understand Risk and Prevention

Slepicka

Cyrill

Santos

2019

Trends in Molecular Medicine

View full text Add to dashboard Cite

show abstract

“…When analyzed according to the absence of HER2 amplification in FISH using the input system could be identified, and specific criteria, such as the HER2/CEP17 ratio, could not be confirmed. Recently, there have been studies in which intrinsic subtype division using gene expression assay (such as PAM50) may be useful for therapeutic response and prognosis prediction [28]. In a typical diagnostic process for HER2, most patients do not require FISH if they have an IHC score of 3+ without FISH.…”

Section: Discussionmentioning

confidence: 99%

Clinical Implications According to Diagnostic Methods of Human Epidermal Growth Factor Receptor 2 Positivity in Breast Cancer: A Retrospective Study

Kim¹,

Jeong²,

Han³

et al. 2018

J Breast Dis

View full text Add to dashboard Cite

Purpose: According to American Society of Clinical Oncology/College of American Pathologists guidelines, breast cancer is human epidermal growth factor receptor 2 (HER2) positive if there is HER2 protein overexpression at a 3+ level on immunohistochemistry (IHC 3+) or gene amplification (more than six copies per nucleus) on fluorescence in situ hybridization (FISH+). However, there have been few reports on whether outcomes differ based on diagnosis by these two techniques. In this study, we compared outcomes based on the two methods in patients with HER2-positive breast cancer. Methods: This study was a retrospective analysis of HER2-positive breast cancer in 18,304 patients, including 14,652 IHC 3+ patients and 3,652 FISH+ patients from the Korean Breast Cancer Society Registry. We compared breast cancer-specific survival and overall survival based on IHC 3+ and FISH+ status with or without trastuzumab. Results: Breast cancer-specific survival was significantly different between the IHC 3+ and FISH+ groups, with 5-year cumulative survival rates of 95.0% for IHC 3+ and 98.5% for FISH+ patients who did not receive trastuzumab (p= 0.001) in Kaplan-Meier methods. However, there were no significant differences in breast cancer-specific survival and overall survival between IHC 3+ and FISH+ groups regardless of trastuzumab treatment in Cox proportional hazards models. Conclusion: The survival outcomes were not affected by the different two diagnostic methods of HER2-positive breast cancer. Further research to evaluate differences in prognosis and other characteristics according to the diagnostic methods of HER2 positivity is needed in the future. Key Words: Breast neoplasms, ErbB-2 receptor, Fluorescence in situ hybridization, Immunohistochemistry, Survival imen heterogeneity and reader subjectivity in the interpretation of HER2 protein expression level [11]. The HER2 in situ hybridization (ISH) method, which measures HER2/neu gene amplification, is used ORIGINAL ARTICLE J Breast Dis 2018 December; 6(2): 60-72 https://doi.

show abstract

“…MammaPrint is a 70 gene assay for women with Stage I or II breast cancer designed to predict the risk of recurrence and thus guide decision making regarding chemotherapy (74). The Prediction Analysis of Microarray 50 (PAM50) assay, also known as Prosigna, is a 50 gene assay designed for women with ER positive, HER2 negative breast cancer to predict the likelihood of metastasis and thus influence decisions regarding hormone therapy and chemotherapy (75). It allows for both classification of intrinsic subtypes as well as generation of a risk of recurrence (ROR) score.…”

Section: Multigene Assaysmentioning

confidence: 99%